News

NIAID ACTIV-2 trial begins Phase 2/3 testing on four COVID-19 therapeutics

Another four COVID-19 therapeutics for those with mild to moderate symptoms moved further up the pipeline this week, with the announcement of enrollment for Phase 2/3 testing in the National Institute of Allergy and Infectious Diseases (NIAID) ACTIV-2 trial.

ACTIV, or the Accelerating COVID-19 Therapeutic Interventions and Vaccines program, was designed to coordinate research and encourage the development of promising COVID-19 treatments and vaccines. ACTIV-2 will involve randomized, placebo-controlled studies of Synairgen’s SNG001 inhalable beta interferon, a monoclonal antibody combination from AstraZeneca known as AZD7442 and Camostat mesilate, an oral serine protease inhibitor created by Sagent Pharmaceuticals.

While the study of SNG001 enrolled its first volunteer last week, the other agents should begin enrollments soon. Any that show promise through sufficient safety and reduction of COVID-19 symptoms over the course of 28 days following administration will be moved to a phase three study to gather data from a larger pool of volunteers immediately. Up to 220 volunteers can be enrolled in the phase two studies, but enrollment size for phase three studies can vary.

The therapeutics will be compared against a shared group of placebo recipients. Participants must have tested positive for SARS-CoV-2 — the virus that causes COVID-19 — within 10 days and started experiencing symptoms within eight days of enrollment. Beyond safety and efficacy, a side goal will be to determine if any of these agents can reduce the amount of SARS-CoV-2 detectable in the nasopharynx.

Led by the NIAID-funded AIDS Clinical Trials Group, the study will also be overseen by an independent data and safety monitoring board.

Chris Galford

Recent Posts

Senate bill seeks to compel national security risk analysis of economic integration with China

A bipartisan group of senators recently introduced the American Economic Independence Act, which would require…

24 hours ago

Sen. Peters presses federal agencies to increase cybersecurity for American health care

Citing cases where cyberattacks targeted health care systems in the United States, U.S. Sen. Gary…

24 hours ago

U.S. Justice Department launches National Extreme Risk Protection Order Resource Center to curb gun violence

The U.S. Department of Justice recently launched a new resource center – the National Extreme…

2 days ago

Government funding agreement includes $3M allotment to create Northern Border security center

Among the provisions included in the recent $1.2 trillion funding agreement signed by President Joe…

2 days ago

Senate advances legislation to streamline support, improve response amid disasters

The Senate recently advanced legislation from U.S. Sens. Gary Peters (D-MI) and John Kennedy (R-LA)…

3 days ago

Raytheon wins $1.2B contract to supply Patriot air and missile defense systems to Germany

Germany seeks to augment its existing air defenses with a new round of Patriot air…

3 days ago

This website uses cookies.